Literature DB >> 22018711

Tolerogen-induced interferon-producing killer dendritic cells (IKDCs) protect against EAE.

Eduardo Huarte1, Agnieszka Rynda-Apple, Carol Riccardi, Jerod A Skyberg, Sarah Golden, Maryclare F Rollins, Andrew G Ramstead, Larissa O Jackiw, Massimo Maddaloni, David W Pascual.   

Abstract

Natural killer (NK) cells and dendritic cells (DCs) have been shown to link the innate and adaptive immune systems. Likewise, a new innate cell subset, interferon-producing killer DCs (IKDCs), shares phenotypic and functional characteristics with both DCs and NK cells. Here, we show IKDCs play an essential role in the resolution of experimental autoimmune encephalomyelitis (EAE) upon treatment with the tolerizing agent, myelin oligodendrocyte glycoprotein (MOG), genetically fused to reovirus protein σ1 (termed MOG-pσ1). Activated IKDCs were recruited subsequent MOG-pσ1 treatment of EAE, and disease resolution was abated upon NK1.1 cell depletion. These IKDCs were able to kill activated CD4(+) T cells and mature dendritic DCs, thus, contributing to EAE remission. In addition, IKDCs were responsible for MOG-pσ1-mediated MOG-specific regulatory T cell recruitment to the CNS. The IKDCs induced by MOG-pσ1 expressed elevated levels of HVEM for interactions with cognate ligand-positive cells: LIGHT(+) NK and T(eff) cells and BTLA(+) B cells. Further characterization revealed these activated IKDCs being MHC class II(high), and upon their adoptive transfer (CD11c(+)NK1.1(+)MHC class II(high)), IKDCs, but not CD11c(+)NK1.1(+)MHC class II(intermediate/low) (unactivated) cells, conferred protection against EAE. These activated IKDCs showed enhanced CD107a, PD-L1, and granzyme B expression and could present OVA, unlike unactivated IKDCs. Thus, these results demonstrate the interventional potency induced HVEM(+) IKDCs to resolve autoimmune disease. 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22018711      PMCID: PMC3237120          DOI: 10.1016/j.jaut.2011.09.005

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  69 in total

Review 1.  Adaptive immune responses mediated by natural killer cells.

Authors:  Silke Paust; Balimkiz Senman; Ulrich H von Andrian
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

2.  The dendritic cell-like functions of IFN-producing killer dendritic cells reside in the CD11b+ subset and are licensed by tumor cells.

Authors:  Magali Terme; Grégoire Mignot; Evelyn Ullrich; Mathieu Bonmort; Véronique Minard-Colin; Alexandra Jacquet; Joachim L Schultze; Guido Kroemer; Claude Leclerc; Nathalie Chaput; Laurence Zitvogel
Journal:  Cancer Res       Date:  2009-08-15       Impact factor: 12.701

Review 3.  Natural killer cells in human autoimmunity.

Authors:  Malin Flodström-Tullberg; Yenan T Bryceson; Fu-Dong Shi; Petter Höglund; Hans-Gustaf Ljunggren
Journal:  Curr Opin Immunol       Date:  2009-11-04       Impact factor: 7.486

Review 4.  Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis.

Authors:  Natalie J Carter; Gillian M Keating
Journal:  Drugs       Date:  2010-08-20       Impact factor: 9.546

5.  The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.

Authors:  Xiaoli Feng; Jie Yan; Yibiao Wang; Juleen R Zierath; Magnus Nordenskjöld; Jan-Inge Henter; Bengt Fadeel; Chengyun Zheng
Journal:  Mol Immunol       Date:  2010-06-09       Impact factor: 4.407

Review 6.  Emerging concepts in autoimmune encephalomyelitis beyond the CD4/T(H)1 paradigm.

Authors:  Helena Batoulis; Klaus Addicks; Stefanie Kuerten
Journal:  Ann Anat       Date:  2010-07-15       Impact factor: 2.698

7.  Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology.

Authors:  Junwei Hao; Ruolan Liu; Wenhua Piao; Qinghua Zhou; Timothy L Vollmer; Denise I Campagnolo; Rong Xiang; Antonio La Cava; Luc Van Kaer; Fu-Dong Shi
Journal:  J Exp Med       Date:  2010-08-09       Impact factor: 14.307

8.  Migratory and antigen presentation functions of IFN-producing killer dendritic cells.

Authors:  Nourredine Himoudi; Mengyong Yan; Gerben Bouma; Daniel Morgenstern; Rebecca Wallace; Ben Seddon; Jo Buddle; Ayad Eddaoudi; Steven J Howe; Nichola Cooper; John Anderson
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

9.  IFN-producing killer dendritic cells are antigen-presenting cells endowed with T-cell cross-priming capacity.

Authors:  Maria Pletneva; Hongni Fan; Jang-June Park; Vedran Radojcic; Chunfa Jie; Yanxing Yu; Camie Chan; Alec Redwood; Drew Pardoll; Franck Housseau
Journal:  Cancer Res       Date:  2009-08-15       Impact factor: 12.701

10.  Both conventional and interferon killer dendritic cells have antigen-presenting capacity during influenza virus infection.

Authors:  Corine H GeurtsvanKessel; Ingrid M Bergen; Femke Muskens; Louis Boon; Henk C Hoogsteden; Albert D M E Osterhaus; Guus F Rimmelzwaan; Bart N Lambrecht
Journal:  PLoS One       Date:  2009-09-28       Impact factor: 3.240

View more
  6 in total

1.  Cutting Edge: Induction of Inflammatory Disease by Adoptive Transfer of an Atypical NK Cell Subset.

Authors:  Elisaveta Voynova; Chen-Feng Qi; Bethany Scott; Silvia Bolland
Journal:  J Immunol       Date:  2015-06-24       Impact factor: 5.422

2.  Regulatory T Cell Dysfunction Acquiesces to BTLA+ Regulatory B Cells Subsequent to Oral Intervention in Experimental Autoimmune Encephalomyelitis.

Authors:  Eduardo Huarte; SangMu Jun; Agnieszka Rynda-Apple; Sara Golden; Larissa Jackiw; Carol Hoffman; Massimo Maddaloni; David W Pascual
Journal:  J Immunol       Date:  2016-05-18       Impact factor: 5.422

3.  Loss of sialic acid binding domain redirects protein σ1 to enhance M cell-directed vaccination.

Authors:  Dagmara Zlotkowska; Massimo Maddaloni; Carol Riccardi; Nancy Walters; Kathryn Holderness; Gayle Callis; Agnieszka Rynda-Apple; David W Pascual
Journal:  PLoS One       Date:  2012-04-30       Impact factor: 3.240

4.  A role for pre-mNK cells in tumor progression.

Authors:  Carolyn Rosinsky; Paul Andrew Antony
Journal:  J Immunother Cancer       Date:  2016-03-15       Impact factor: 13.751

5.  Depletion of B220+NK1.1+ cells enhances the rejection of established melanoma by tumor-specific CD4+ T cells.

Authors:  Kyle A Wilson; Stephen R Goding; Harold R Neely; Kristina M Harris; Paul Andrew Antony
Journal:  Oncoimmunology       Date:  2015-04-01       Impact factor: 8.110

Review 6.  Revisiting the Prominent Anti-Tumoral Potential of Pre-mNK Cells.

Authors:  Fanny Guimont-Desrochers; Sylvie Lesage
Journal:  Front Immunol       Date:  2013-12-11       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.